ABSTRACT
Chemotherapy-induced peripheral neuropathy is one of the most common treatmentlimiting side effects of cancer therapy. Strategies to prevent or limit chemotherapyinduced peripheral neuropathy have not been generally effective. While peripheral neuropathy might resolve partially or completely when treatment is stopped, some cases of chemotherapy-induced peripheral neuropathy are irreversible. Peripheral neuropathy has been associated with particular chemotherapeutic drugs or classes: platinum agents, taxanes, vinca alkaloids, bortezomib, thalidomide, lanilomide, suramin, and epothilones. Chemotherapy-induced peripheral neuropathy can be complex to analyze, in that there is considerable interpatient variability, the condition does not consistently appear to be dose dependent, and it may be mistaken for neurological de•cits associated with the malignancy. This review of recent clinical trials highlights the agents known to be associated with peripheral neuropathy along with the rates of treatment-emergent peripheral neuropathy.
